Key facts
- Pfizer announced mid-stage trial data for its GLP-1 therapy.
- The data support a monthly dosing schedule for the therapy.
- This development could offer a more convenient treatment option for patients.
Pfizer has announced that mid-stage trial data support a monthly dosing schedule for its GLP-1 therapy. This development is significant as it could offer a more convenient treatment option for patients seeking weight-loss solutions. The company is actively pursuing a position in the lucrative obesity market, and this data supports their strategy.